The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances

NCT ID: NCT01054664

Last Updated: 2010-01-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the incidence of occult hepatitis C virus in hemodialysed patients with mild impairment of liver enzymes

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

occult hepatitis C virus will be checked in monocytes of hemodialyzed patients with permanent mild impairment of liver enzymes This population has no evidence of hepatitis B or C according to standard laboratory tests (HVC antibodies,HCV PCR, hepatitis B antibodies) Hepatitis C virus RNA will be performed in peripheral blood mononuclear cells of hemodialysed patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodialysed Patients With Impaired Liver Enzymes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

impaired liver enzymes

No interventions assigned to this group

normal liver enzymes

No interventions assigned to this group

hepatitis C antibodies positive

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hemodialysed patients with impaired liver enzymes

Exclusion Criteria

* hepatitis B and C positive
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meir Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Clalit Health services

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Plotkin Eleonora

Kfar Saba, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eleonora Plotkin, MD

Role: CONTACT

972 9 7472517

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Osnat Klein, MD

Role: primary

972 9 7472517

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

nephrop003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HCV Virions Bound Proteins
NCT02795403 COMPLETED NA